Anti-Diabetes Drugs - Jamaica | Statista Market Forecast

The Anti-Diabetes Drugs market in Jamaica is expected to witness a significant increase in revenue, reaching a projected value of US$9.91m in 2024.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 6.82%, leading to a market volume of US$13.78m by 2029.
When compared globally, United States is set to generate the highest revenue in this market, with a staggering amount of US$37.84bn in 2024.
Jamaica has seen a surge in the demand for locally sourced herbal remedies as an alternative to traditional anti-diabetes drugs.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Jamaica is experiencing significant growth in recent years.

Customer preferences: Jamaicans are becoming more health-conscious and aware of the importance of managing diabetes. This has led to an increased demand for anti-diabetes drugs in the country. Additionally, the aging population in Jamaica is also contributing to the growth of the market as diabetes is more prevalent among older individuals.

Trends in the market: The market for anti-diabetes drugs in Jamaica is dominated by oral medications, which are preferred by patients due to their ease of use. However, there is a growing trend towards the use of injectable medications, such as insulin, which are more effective in managing diabetes. This trend is driven by the increasing prevalence of Type 2 diabetes in Jamaica, which requires more aggressive treatment options.

Local special circumstances: Jamaica has a high prevalence of diabetes, with approximately 1 in 8 adults living with the disease. This has led to a significant burden on the country's healthcare system, with diabetes-related complications accounting for a significant portion of hospital admissions and healthcare costs. As a result, the government has implemented initiatives to promote diabetes awareness and prevention, which has contributed to the growth of the anti-diabetes drugs market.

Underlying macroeconomic factors: Jamaica's economy has been growing steadily in recent years, with a focus on developing the healthcare sector. This has led to increased investment in healthcare infrastructure and services, which has contributed to the growth of the anti-diabetes drugs market. Additionally, the country's population is projected to continue aging, which will drive further growth in the market as the prevalence of diabetes increases with age.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.